Business Context and Reporting Period
Kura Oncology, Inc. filed this Form 8-K on May 11, 2021, to report the entry into a material definitive agreement. The company is a biopharmaceutical entity incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new lease agreement.
- Lease Term: 48 months.
- Commencement Date: Expected August 10, 2021.
- Minimum Rent: Approximately $23,700 per month for the first year.
- Rent Escalation: 3.0% annual increase over the lease term.
- Additional Costs: Company responsible for its share of operating expenses, taxes, and utilities.
Material Changes
The material change reported is the execution of a lease for approximately 5,315 square feet of rentable space at 5510 Morehouse Drive, San Diego, California. The space is intended for laboratory and general office use. This creates a new direct financial obligation for the registrant.
Outlook, Risks, and Contingencies
The filing notes that in the event of a default on certain obligations, the Landlord retains the right to terminate the lease and recover unpaid rent and expenses. The full text of the lease agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the total committed capital outlay for the 48-month lease term including estimated operating expenses.
- Confirm the impact of the new lease obligation on the company's future cash flow projections.
- Review the upcoming Form 10-Q for the full text of the lease agreement to assess specific default clauses and termination rights.
- Assess whether the 5,315 square feet aligns with the company's current and projected R&D capacity needs.